

R²
com.

nitrogen; and G is oxygen, sulfur or NR⁴, with the proviso that when E and F are both nitrogen, one of R⁹ and R¹⁰ is absent; and

R⁷ and R⁸ are independently selected from the group consisting of hydrogen, (C₁-C₆) alkyl, (C₁-C₆) alkoxy carbonyl, (C₁-C₆) alkyl carbonyl, and (C₁-C₆) alkoxy, with the proviso that said (C₁-C₆) alkoxy is not attached to a carbon that is adjacent to a nitrogen; or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier.


IN THE CLAIMS:

R³

Please cancel Claim 10 without prejudice.

Please amend Claims 1, 3, 4, 5, 6, 7, 8, 11, 12, 14, 15, 19, and 20 as follows:


1. (Amended) A method of treating an age-related behavioral disorder in a companion animal comprising administering to a companion animal in need of such treatment a therapeutically effective amount of a compound of Formula I,



wherein R¹ and R² are each independently selected from the group consisting of hydrogen; (C₁-C₆) alkoxy; benzyloxy; phenoxy; hydroxy; phenyl; benzyl; halo; nitro; cyano; -COR⁵; -COOR⁵; -CONHR⁵; -NR⁵R⁶; -NR⁵COR⁶; -OCONR⁵R⁶; -NHCOOR⁵; (C₁-C₆) alkyl which may be substituted with from 1 to 3 fluorine atoms; SO_pCH₂-phenyl or SO_p(C₁-C₆) alkyl, wherein p is 0, 1 or 2; pyridylmethoxy or thienylmethoxy; 2-oxazolyl; 2-thiazolyl; and

John P.
benzenesulfonamide; wherein the phenyl moieties of said phenoxy, benzyloxy, phenyl, benzyl and benzenesulfonamide groups, the pyridyl and thieryl moieties of said pyridylmethoxy or thierylmethoxy groups, and the oxazolyl and thiazolyl moieties of said 2-oxazolyl and 2-thiazolyl groups may be substituted with 1 or 2 substituents independently selected from the group consisting of halo, (C₁-C₄) alkyl, trifluoromethyl, (C₁-C₄) alkoxy, cyano, nitro and hydroxy;

*23
cont.*
or R¹ and R² are attached to adjacent carbon atoms and form, together with the carbon atoms to which they are attached, a group of Formula 2:



FORMULA 2

wherein R³ is hydrogen or (C₁-C₆) alkyl; J is oxygen, sulfur or NR⁴; R⁴ is hydrogen or (C₁-C₄) alkyl; and Q is oxygen, sulfur, NH, CHCH₃, C(CH₃)₂, -CH=CH-, or (CH₂)_I) wherein I is an integer from 1 to 3;


X is oxygen or sulfur;

Y is -(CH₂)_m-, -CH=CH(CH₂)_n-, or -O(CH₂)_m-, wherein n is an integer from 0 to 3, and m is an integer from 1 to 3;

R⁵ and R⁶ are each independently selected from the group consisting of hydrogen, (C₁-C₆) alkyl, phenyl, and benzyl, wherein the phenyl moieties of said phenyl and benzyl groups may be substituted with 1 or 2 substituents independently selected from the group consisting of fluoro, chloro, bromo, iodo, (C₁-C₄) alkyl, trifluoromethyl, (C₁-C₄) alkoxy, cyano, nitro and hydroxy; or NR⁵R⁶ together form a 4 or 5 membered ring wherein one atom of the ring is

[Signature]
nitrogen and the other are carbon, oxygen or nitrogen; or NR^5COR^6 together form a 4- or 5-membered lactam ring;

[Signature]
L is phenyl, phenyl-(C₁-C₆) alkyl, cinnamyl or pyridylmethyl, wherein the phenyl moieties of said phenyl and phenyl-(C₁-C₆) alkyl may be substituted with 1 to 3 substituents independently selected from the group consisting of (C₁-C₆) alkyl, (C₁-C₆) alkoxy, (C₁-C₄) alkoxy carbonyl, (C₁-C₆) alkyl carbonyl, -OCONR⁵R⁶, -NHCOOR⁵, and halo; or L is a group of Formula 3:



FORMULA 3

wherein b is an integer from 1 to 4; R⁹ and R¹⁰ are independently selected from the group consisting of hydrogen, (C₁-C₄) alkyl, halo, and phenyl; E and F are independently -CH- or nitrogen; and G is oxygen, sulfur or NR⁴, with the proviso that when E and F are both nitrogen, one of R⁹ and R¹⁰ is absent; and

[Signature]
R⁷ and R⁸ are independently selected from the group consisting of hydrogen, (C₁-C₆) alkyl, (C₁-C₆) alkoxy carbonyl, (C₁-C₆) alkyl carbonyl, and (C₁-C₆) alkoxy, with the proviso that said (C₁-C₆) alkoxy is not attached to a carbon that is adjacent to a nitrogen; or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier.

[Signature]
3. (Amended) A method of improving the cognitive processing of a companion animal comprising administering to a companion animal in need of such improvement an amount of a compound of Formula I sufficient to improve cognitive processing.

[Signature]
4. (Amended) A method of treating memory loss in a companion animal comprising administering to a companion animal in need of such improvement an amount of a compound of Formula I sufficient to improve cognitive processing.

[Signature]
5. (Amended) A method of treating disorientation or confusion in a companion animal comprising administering to a companion animal in need of such treatment a therapeutically effective amount of a compound of Formula I.

[Signature]
6. (Amended) A method of improving the social interactions of a companion animal comprising administering to a companion animal in need of such improvement a therapeutically effective amount of a compound of Formula I.

[Signature]
7. (Amended) A method of adjusting the sleep-wake cycle of a companion animal comprising administering to a companion animal in need of such adjustment a therapeutically effective amount of a compound of Formula I.

[Signature]
8. (Amended) A method of treating inappropriate elimination in a companion animal comprising administering to a companion animal in need of such treatment a therapeutically effective amount of a compound of Formula I.

[Signature]
11. (Amended) The method of Claim 10 wherein the compound of Formula 1 is selected from the group consisting of:

[Signature]
5,7-dihydro-7-methyl-3-[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]-6H-pyrrolo[4,5-f]-1,2-benzisoxazol-6-one;

[Signature]
5,7-dihydro-7-ethyl-3-[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]-6H-pyrrolo[4,5-f]-1,2-benzisoxazol-6-one;

[Signature]
5,7-dihydro-3-[2-[1-(2-chloro-5-thiophenemethyl)-4-piperidinyl]ethyl]-6H-pyrrolo[4,5-f]-1,2-benzisoxazol-6-one;

Sub C1 cont
5,7-dihydro-3-[2-[1-(2-methyl-4-thiazolemethyl)-4-piperidinyl]ethyl]-6H-pyrrolo[4,5-f]-1,2-benzisoxazol-6-one;

3-[2-[1-(3-bromophenylmethyl)-4-piperidinyl]ethyl]-5,7-dihydro-6H-pyrrolo[4,5-f]-1,2-benzisoxazol-6-one;

3-[2-[1-(4-bromophenylmethyl)-4-piperidinyl]ethyl]-5,7-dihydro-6H-pyrrolo[4,5-f]-1,2-benzisoxazol-6-one;

5,7-dihydro-3-[3-[1-(phenylmethyl)-4-piperidinyl]propyl]-6H-pyrrolo[4,5-f]-1,2-benzisoxazol-6-one;

6,8-dihydro-3-[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]-7H-pyrrolo[5,4-g]-1,2-benzisoxazol-7-one; and

5,7-dihydro-3-[2-(1-(phenylmethyl)-4-piperidinyl)ethyl]-6H-pyrrolo[4,5-f]-1,2-benzisoxazol-6-one.

12. (Amended) The method of Claim 11 wherein the compound of Formula I is 5,7-dihydro-3-[2-(1-(phenylmethyl)-4-piperidinyl)ethyl]-6H-pyrrolo[4,5-f]-1,2-benzisoxazol-6-one.

14. (Amended) The pharmaceutical composition of Claim 13 wherein the compound of Formula I is selected from the group consisting of:

5,7-dihydro-7-methyl-3-[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]-6H-pyrrolo[4,5-f]-1,2-benzisoxazol-6-one;

5,7-dihydro-7-ethyl-3-[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]-6H-pyrrolo[4,5-f]-1,2-benzisoxazol-6-one;

5,7-dihydro-3-[2-[1-(2-chloro-5-thiophenemethyl)-4-piperidinyl]ethyl]-6H-pyrrolo[4,5-f]-1,2-benzisoxazol-6-one;

5,7-dihydro-3-[2-[1-(2-methyl-4-thiazolemethyl)-4-piperidinyl]ethyl]-6H-pyrrolo[4,5-f]-1,2-benzisoxazol-6-one;

3-[2-[1-(3-bromophenylmethyl)-4-piperidinyl]ethyl]-5,7-dihydro-6H-pyrrolo[4,5-f]-1,2-benzisoxazol-6-one;

3-[2-[1-(4-bromophenylmethyl)-4-piperidinyl]ethyl]-5,7-dihydro-6H-pyrrolo[4,5-f]-1,2-benzisoxazol-6-one;

5,7-dihydro-3-[3-[1-(phenylmethyl)-4-piperidinyl]propyl]-6H-pyrrolo[4,5-f]-1,2-benzisoxazol-6-one;

6,8-dihydro-3-[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]-7H-pyrrolo[5,4-g]-1,2-benzisoxazol-7-one; and

5,7-dihydro-3-[2-(1-(phenylmethyl)-4-piperidinyl)ethyl]-6H-pyrrolo[4,5-f]-1,2-benzisoxazol-6-one.

15. (Amended) The pharmaceutical composition of claim 14 wherein the compound of Formula I is 5,7-dihydro-3-[2-(1-(phenylmethyl)-4-piperidinyl)ethyl]-6H-pyrrolo[4,5-f]-1,2-benzisoxazol-6-one.

19. (Amended) The dosage form of Claim 18 wherein the compound of Formula I is selected from the group consisting of:

5,7-dihydro-7-methyl-3-[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]-6H-pyrrolo[4,5-f]-1,2-benzisoxazol-6-one;

5,7-dihydro-7-ethyl-3-[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]-6H-pyrrolo[4,5-f]-1,2-benzisoxazol-6-one;

5,7-dihydro-3-[2-[1-(2-chloro-5-thiophenemethyl)-4-piperidinyl]ethyl]-6H-pyrrolo[4,5-f]-1,2-benzisoxazol-6-one;